Consumption of clotting factors in severe haemophilia patients undergoing prophylaxis and on-demand treatment in Italy

Transfusion Medicine

Volumn 21, Issue 4, 2011, Pages 280-284

  Giampaolo, A ^a   Abbonizio, F ^a   Puopolo, M ^b   Arcieri, R ^c   Mannucci, P M ^d   Hassan, H J ^a  

^a Oncology and Molecular Medicine ^*  (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c Federation of Haemophiliac Associations   (Italy)

^d FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; PLASMA DERIVED BLOOD CLOTTING FACTOR 8; PLASMA DERIVED BLOOD CLOTTING FACTOR 9; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGE; BLEEDING; CHILD; DISEASE SEVERITY; DRUG USE; HEALTH SURVEY; HEMOPHILIA A; HEMOPHILIA B; HUMAN; IMMUNOLOGICAL TOLERANCE; ITALY; LETTER; MAJOR CLINICAL STUDY; PRESCHOOL CHILD; PROPHYLAXIS; SCHOOL CHILD; TREATMENT DURATION; VASCULAR ACCESS; WEIGHT GAIN;

FACTOR IX; FACTOR VIII; FEMALE; HEMOPHILIA A; HEMOPHILIA B; HUMANS; ITALY; MALE; QUESTIONNAIRES;

EID: 79960142103     PISSN: 09587578     EISSN: 13653148     Source Type: Journal    
DOI: 10.1111/j.1365-3148.2011.01074.x     Document Type: Letter

References (12)

1. Berntorp, E., Boulyjenkov, V., Brettler, D. et al. (1995) Modern treatment of haemophilia. Bulletin of the World Health Organization, 73, 691-701.
2. Biss, T.T., Chan, A.K., Blanchette, V.S., Iwenofu, L.N., McLimont, M., Carcao, M.D., Association of Hemophilia Clinic Directors of Canada (AHCDC) & Canadian Association of Nurses in Hemophilia Care (CANHC). (2008) The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey. Haemophilia, 14, 923-930.
3. Manco-Johnson, M.J., Abshire, T.C., Shapiro, A.D. et al. (2007) Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. The New England Journal of Medicine, 357, 535-544.
4. Mannucci, P.M., Schutgens, R.E.G., Santagostino, E. & Mauser-Bunschoten, E.P. (2009) How I treat age-related morbidities in elderly persons with hemophilia. Blood, 114, 5256-5263.
5. Ofosu, F.A., Freedman, J. & Semple, J.W. (2008) Plasma-derived biological medicines used to promote haemostasis. Thrombosis and Haemostasis, 99, 851-862.
6. Roosendaal, G. & Lafeber, F. (2007) Prophylactic treatment for prevention of joint disease in hemophilia - cost versus benefit. The New England Journal of Medicine, 357, 603-605.
7. Santagostino, E., Mannucci, P.M. & Bianchi Bonomi, A. (2000) Guidelines on replacement therapy for haemophilia and inherited coagulation disorders in Italy. Haemophilia, 6, 1-10.
8. Stonebraker, J.S., Brooker, M., Amand, R.E., Farrugia, A. & Srivastava, A. (2010) A study of reported factor VIII use around the world. Haemophilia, 16, 33-46.
9. Tagariello, G., Iorio, A., Santagostino, E. et al. (2009) Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders. Blood, 114, 779-784.
10. United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO). UK Bleeding Disorder Statistics for 2007. Annual Report (2008). Available at (Accessed 8/4/10).
11. World Federation of Hemophilia. (2008) Report on The Annual Global Survey 2007. WFH, Montreal, Canada. Available at (Accessed 8/4/10).
12. World Health Organization. (2002) Delivery of treatment for haemophilia. Report of a Joint WHO/WFH/ISTH Meeting. WHO, London, United Kingdom. Available at (Accessed 8/4/10).